Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $24.4800 (0.7%) ($23.1600 - $24.9800) on Fri. Jan. 8, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 10.94% (three month average) | RSI | 81 | Latest Price | $24.4800(0.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -3% a day on average for past five trading days. | Weekly Trend | ADMS advances 11.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(36%) IBB(34%) ARKG(25%) IWO(23%) IWM(22%) | Factors Impacting ADMS price | ADMS will decline at least -5.47% in a week (0% probabilities). VIXM(-15%) BNDX(-9%) UUP(-8%) TLT(-7%) SHY(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.47% (StdDev 10.94%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
5 Day Moving Average | $25.28(-3.16%) | 10 Day Moving Average | $27.06(-9.53%) | 20 Day Moving Average | $22.35(9.53%) | To recent high | -20.6% | To recent low | 83.6% | Market Cap | $692m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |